PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29309760-7 2018 Further studies indicated that rosiglitazone stimulated SIRT1 deacetylase leading to PGC1alpha translocation from the cytosol into the nucleus, promoting fragmentation of NCoR and phosphorylation of PPARgamma. Rosiglitazone 31-44 PPARG coactivator 1 alpha Homo sapiens 85-94 29309760-9 2018 These results suggested that rosiglitazone-induced HO-1 expression is mediated through PKCalpha/AMPKalpha/p38 MAPKalpha/SIRT1-dependent deacetylation of Ac-PGC1alpha and fragmentation of NCoR/PPARgamma activation in HPAEpiCs. Rosiglitazone 29-42 PPARG coactivator 1 alpha Homo sapiens 156-165 24898700-7 2014 Treatment by rosiglitazone sustained PGC-1alpha and Mfn2 expression both in IR livers, and L02 cells treated with TNF-alpha as indicated by increased hepatic mitochondrial integrity and ATP production, reduced ROS and ALT activity as well as decreased cell apoptosis. Rosiglitazone 13-26 PPARG coactivator 1 alpha Homo sapiens 37-47 28964868-6 2017 The stimulation of mitochondrial function and anti-oxidative stress by rosiglitazone was associated with activation of the PGC1alpha pathway by up-regulation of mitochondrial (NRF-1 and Tfam) and oxidative defense (SOD1, SOD2 and Gpx1) genes. Rosiglitazone 71-84 PPARG coactivator 1 alpha Homo sapiens 123-132 26973118-6 2016 Rosiglitazone co-treated hNSCs also showed significantly increased mitochondrial function (reflected by levels of adenosine triphosphate and Mit mass), and PPARgamma-dependent mRNA upregulation of PGC1alpha and mitochondrial genes (nuclear respiratory factor-1 and Tfam). Rosiglitazone 0-13 PPARG coactivator 1 alpha Homo sapiens 197-206 23554809-6 2013 We conclude that rosiglitazone and forskolin act together to synergistically activate the UCP1 promoter directly rather than by increasing PGC1alpha expression and by a mechanism involving cross-talk between the signalling systems regulating the CRE and PPRE on the promoters. Rosiglitazone 17-30 PPARG coactivator 1 alpha Homo sapiens 139-148 23426382-1 2013 OBJECTIVE: The aim of this study was to examine the effect of single nucleotide polymorphisms in CYP2C8, LPIN1, PPARGC1A and PPARgamma on rosiglitazone"s (i) trough steady-state plasma concentration (C(ss,min)), (ii) on glycosylated haemoglobin A1c (HbA1c) and (iii) the risk of developing adverse events, mainly oedema, in patients with type 2 diabetes mellitus (T2D). Rosiglitazone 138-151 PPARG coactivator 1 alpha Homo sapiens 112-120 24606795-49 2014 Among the promising strategies to ameliorate mitochondrial-based diseases these authors highlight the induction of PGC-1alpha via activation of PPAR receptors (rosiglitazone, bezafibrate) or modulating its activity by AMPK (AICAR, metformin, resveratrol) or SIRT1 (SRT1720 and several isoflavone-derived compounds). Rosiglitazone 160-173 PPARG coactivator 1 alpha Homo sapiens 115-125 23554809-2 2013 In HIB1B brown preadipocytes, combination of the PPARgamma agonist, rosiglitazone, and the cAMP stimulator forskolin synergistically increased UCP1 mRNA expression, but PGC1alpha expression was only increased additively by the two drugs. Rosiglitazone 68-81 PPARG coactivator 1 alpha Homo sapiens 169-178 18469005-1 2008 The functional interaction between the peroxisome proliferator-activated receptor gamma (PPARgamma) and its coactivator PGC-1alpha is crucial for the normal physiology of PPARgamma and its pharmacological response to antidiabetic treatment with rosiglitazone. Rosiglitazone 245-258 PPARG coactivator 1 alpha Homo sapiens 120-130 20498286-0 2010 Effects of the peroxisome proliferator activated receptor-gamma coactivator-1alpha (PGC-1alpha) Thr394Thr and Gly482Ser polymorphisms on rosiglitazone response in Chinese patients with type 2 diabetes mellitus. Rosiglitazone 137-150 PPARG coactivator 1 alpha Homo sapiens 15-82 20498286-0 2010 Effects of the peroxisome proliferator activated receptor-gamma coactivator-1alpha (PGC-1alpha) Thr394Thr and Gly482Ser polymorphisms on rosiglitazone response in Chinese patients with type 2 diabetes mellitus. Rosiglitazone 137-150 PPARG coactivator 1 alpha Homo sapiens 84-94 20498286-1 2010 The objective was to investigate whether peroxisome proliferator activated receptor-gamma coactivator-1alpha (PGC-1alpha) Thr394Thr and Gly482Ser polymorphisms influence rosiglitazone response in Chinese patients with type 2 diabetes mellitus. Rosiglitazone 170-183 PPARG coactivator 1 alpha Homo sapiens 41-108 20498286-1 2010 The objective was to investigate whether peroxisome proliferator activated receptor-gamma coactivator-1alpha (PGC-1alpha) Thr394Thr and Gly482Ser polymorphisms influence rosiglitazone response in Chinese patients with type 2 diabetes mellitus. Rosiglitazone 170-183 PPARG coactivator 1 alpha Homo sapiens 110-120 20498286-5 2010 These data suggest that the PGC-1alpha Thr394Thr and Gly482Ser polymorphisms are associated with therapeutic efficacy of multiple-dose rosiglitazone in Chinese patients with type 2 diabetes mellitus. Rosiglitazone 135-148 PPARG coactivator 1 alpha Homo sapiens 28-38 20028987-2 2010 Examining precursors from the purest white adipose tissue depot (epididymal), we report here that chronic treatment with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone promotes not only the expression of PGC-1alpha and mitochondriogenesis in these cells but also a norepinephrine-augmentable UCP1 gene expression in a significant subset of the cells, providing these cells with a genuine thermogenic capacity. Rosiglitazone 182-195 PPARG coactivator 1 alpha Homo sapiens 232-242 21113404-6 2010 The addition of a PPAR-beta agonist (L165,041) for the final 24 hours of 1% treatment resulted in increased levels of UCP-2 mRNA and protein whereas Rosiglitazone induced SIRT1, PGC-1alpha, RXR-alpha, PPAR-alpha, CPT-1b, and UCP-2 mRNA and SIRT1 protein. Rosiglitazone 149-162 PPARG coactivator 1 alpha Homo sapiens 178-188 17184171-6 2007 PGC-1alpha expressed in human aortic smooth (HASMCs) and endothelial cells (HAECs) is upregulated by AMP-activated protein kinase activators, including metformin, rosiglitazone and alpha-lipoic acid. Rosiglitazone 163-176 PPARG coactivator 1 alpha Homo sapiens 0-10 17310221-0 2007 Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus. Rosiglitazone 123-136 PPARG coactivator 1 alpha Homo sapiens 70-81 17310221-9 2007 Rosiglitazone significantly increased PGC-1 alpha ( approximately 2.2-fold, P<0.01) and PPAR beta/delta ( approximately 2.6-fold, P<0.01), in parallel with an increase in insulin sensitivity, SDH activity and metabolic flexibility (P<0.01). Rosiglitazone 0-13 PPARG coactivator 1 alpha Homo sapiens 38-49 17310221-12 2007 CONCLUSION: These results suggest that the insulin-sensitizing effect of rosiglitazone may involve an effect on muscular oxidative capacity, via PGC-1 alpha and PPAR beta/delta, independent of mitochondrial protein content and/or changes in intramyocellular lipid. Rosiglitazone 73-86 PPARG coactivator 1 alpha Homo sapiens 145-156 15864539-8 2005 Exposure to insulin, rosiglitazone or metformin increased mRNA expression of PGC1 and GLUT4, while AICAR or 25 mmol/l glucose treatment increased GLUT1 mRNA expression. Rosiglitazone 21-34 PPARG coactivator 1 alpha Homo sapiens 77-81 12807871-10 2003 The PPAR gamma agonist rosiglitazone potentiated the effect of PGC-1 alpha on UCP1 expression and fatty acid oxidation. Rosiglitazone 23-36 PPARG coactivator 1 alpha Homo sapiens 63-74